Hepatitis B reactivation during combination chemotherapy for AIDS-related lymphoma is uncommon and does not adversely affect outcome

Authors:

Abstract
Here, patients with biopsy-proven systemic AIDS-related lymphoma (ARL) who received combination cytotoxic chemotherapy with curative intent were identified from a cohort of 5832 HIV-1–positive individuals followed up in the highly active antiretroviral therapy (HAART) era, commenced in 1996 (when HAART became freely available to our patients). HBV core (total) antibodies and the presence of HBV surface antigen were detected on stored sequential samples from these patients using the Axsym system (Abbott Laboratories, Chicago, IL). In those individuals who tested positive for HBV core antibodies and were surface-antigen negative, detection and quantification of HBV DNA were performed using real-time polymerase chain reactions (RealArt HBV RG PCR; Artus, Hamburg, Germany). Patient samples were obtained before, during, and following cytotoxic chemotherapy to be examined for evidence of chemotherapy-induced HBV reactivation. All patients were from the Chelsea and Westminster Hospital, one of the largest HIV cohorts in Europe, and the study received appropriate ethical approval.

This publication has 10 references indexed in Scilit: